Loading
Life sciences · Journal article
International Journal of Molecular Sciences · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Prostate cancer (PCa) is one of the leading causes of cancer-related death among men worldwide. Considerable efforts have been devoted to developing more effective therapeutic strategies for PCa, particularly for metastatic castration-resistant prostate cancer (mCRPC), wherein resistance to androgen-receptor pathway inhibition remains a major clinical challenge. G protein-coupled receptors (GPCRs), the largest family of cell surface signaling receptors, regulate numerous physiological and pathological processes and represent major therapeutic targets across multiple diseases, including cancer. In PCa, hormone- and inflammation-related GPCRs have emerged as key regulators of tumor initiation, progression, therapeutic resistance, and metastasis. Accordingly, understanding the contribution of GPCR signaling to PCa biology may reveal novel opportunities for therapeutic intervention, particularly in mCRPC. In this review, we summarize the current knowledge on the expression and function of GPCRs in PCa development, progression, and metastasis, highlighting their potential as therapeutic targets and discussing opportunities for drug development, combination therapies, and drug repurposing.